Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Cancer Cell|March 3, 2009
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisJohn M L Ebos, Christina R Lee, William Cruz-Munoz, et al.
Cell Reports|December 28, 2018
A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy WithdrawalMichalis Mastri, Amanda Tracz, Christina R Lee, et al.
Plos Computational Biology|February 26, 2020
Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumorsCristina Vaghi, Anne Rodallec, Raphaëlle Fanciullino, et al.
Molecular Cancer Research : MCR|July 6, 2004
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasmaJohn M L Ebos, Guido Bocci, Shan Man, et al.
Current Cancer Drug Targets|November 25, 2005
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic doseYuval Shaked, Guido Bocci, Raquel Munoz, et al.
Molecular Cancer Therapeutics|October 18, 2005
Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agentsGiulio Francia, Shane K Green, Guido Bocci, et al.
The Journal of Biological Chemistry|June 5, 2003
Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganizationZubin Master, Jennifer Tran, Aseem Bishnoi, et al.
Molecular Cancer Therapeutics|May 1, 2024
A senescence-mimicking (senomimetic) VEGFR TKI side-effect primes tumor immune responses via IFN/STING signalingMelissa Dolan, Yuhao Shi, Michalis Mastri, et al.
Molecular Cancer Therapeutics|June 19, 2024
A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING SignalingMelissa Dolan, Yuhao Shi, Michalis Mastri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independentAnthony J Mutsaers, Giulio Francia, Shan Man, et al.
Pageof 4